All In Biotech

Drug Trial Radar · NCT06171048

Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects

A Pharmacokinetics Study of CM310 Recombinant Humanized Monoclonal Antibody Injection in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Dec 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 236 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

236

Planned (sponsor's estimate)

Start

Apr 30, 2024

Primary completion

Apr 30, 2025

Study completion Apr 30, 2025

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Dec 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 20 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, randomized, open-label study to evaluate the pharmacokinetics of CM310 in healthy subjects.

Conditions

  • Healthy

Interventions

  • CM310Biological

    CM310 injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic: the maximum concentration (Cmax)Time frame: up to week 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.